S&P 500   3,322.45 (-0.22%)
DOW   29,317.02 (-0.11%)
QQQ   222.93 (-0.20%)
AAPL   317.89 (-0.26%)
FB   221.93 (-0.09%)
MSFT   167.13 (+0.02%)
GOOGL   1,481.24 (+0.12%)
AMZN   1,867.64 (+0.16%)
CGC   25.17 (+1.12%)
BABA   220.93 (-2.86%)
TSLA   533.43 (+4.49%)
AMD   51.18 (+0.49%)
T   38.35 (-0.08%)
F   9.14 (-0.22%)
NFLX   339.67 (+0.00%)
PRI   127.81 (-0.48%)
BAC   34.71 (+0.00%)
GILD   62.75 (-0.37%)
DIS   144.38 (+0.03%)
S&P 500   3,322.45 (-0.22%)
DOW   29,317.02 (-0.11%)
QQQ   222.93 (-0.20%)
AAPL   317.89 (-0.26%)
FB   221.93 (-0.09%)
MSFT   167.13 (+0.02%)
GOOGL   1,481.24 (+0.12%)
AMZN   1,867.64 (+0.16%)
CGC   25.17 (+1.12%)
BABA   220.93 (-2.86%)
TSLA   533.43 (+4.49%)
AMD   51.18 (+0.49%)
T   38.35 (-0.08%)
F   9.14 (-0.22%)
NFLX   339.67 (+0.00%)
PRI   127.81 (-0.48%)
BAC   34.71 (+0.00%)
GILD   62.75 (-0.37%)
DIS   144.38 (+0.03%)
S&P 500   3,322.45 (-0.22%)
DOW   29,317.02 (-0.11%)
QQQ   222.93 (-0.20%)
AAPL   317.89 (-0.26%)
FB   221.93 (-0.09%)
MSFT   167.13 (+0.02%)
GOOGL   1,481.24 (+0.12%)
AMZN   1,867.64 (+0.16%)
CGC   25.17 (+1.12%)
BABA   220.93 (-2.86%)
TSLA   533.43 (+4.49%)
AMD   51.18 (+0.49%)
T   38.35 (-0.08%)
F   9.14 (-0.22%)
NFLX   339.67 (+0.00%)
PRI   127.81 (-0.48%)
BAC   34.71 (+0.00%)
GILD   62.75 (-0.37%)
DIS   144.38 (+0.03%)
S&P 500   3,322.45 (-0.22%)
DOW   29,317.02 (-0.11%)
QQQ   222.93 (-0.20%)
AAPL   317.89 (-0.26%)
FB   221.93 (-0.09%)
MSFT   167.13 (+0.02%)
GOOGL   1,481.24 (+0.12%)
AMZN   1,867.64 (+0.16%)
CGC   25.17 (+1.12%)
BABA   220.93 (-2.86%)
TSLA   533.43 (+4.49%)
AMD   51.18 (+0.49%)
T   38.35 (-0.08%)
F   9.14 (-0.22%)
NFLX   339.67 (+0.00%)
PRI   127.81 (-0.48%)
BAC   34.71 (+0.00%)
GILD   62.75 (-0.37%)
DIS   144.38 (+0.03%)
Log in
(Ad)
A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.

This is undoubtedly the beginning of the end for "Big 3" internet providers.

Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.

NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News

$43.81
+0.15 (+0.34 %)
(As of 01/21/2020 09:45 AM ET)
Today's Range
$42.58
Now: $43.81
$44.21
50-Day Range
$28.01
MA: $35.63
$43.66
52-Week Range
$6.16
Now: $43.81
$43.89
Volume49,922 shs
Average Volume655,048 shs
Market Capitalization$2.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.88 million
Book Value$0.29 per share

Profitability

Net Income$-37,970,000.00
Net Margins-143.30%

Miscellaneous

Employees76
Market Cap$2.54 billion
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Could 5G be the greatest investment opportunity of 2020?

Our President, Donald J. Trump has said...

Click here to receive your free report

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) released its quarterly earnings data on Monday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.06. The biopharmaceutical company had revenue of $10.58 million for the quarter, compared to analysts' expectations of $7.83 million. ChemoCentryx had a negative net margin of 143.30% and a negative return on equity of 88.76%. View ChemoCentryx's Earnings History.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx.

What price target have analysts set for CCXI?

7 Wall Street analysts have issued 12-month price objectives for ChemoCentryx's shares. Their forecasts range from $22.00 to $56.00. On average, they expect ChemoCentryx's share price to reach $41.33 in the next year. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for ChemoCentryx.

What is the consensus analysts' recommendation for ChemoCentryx?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:
  • 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (1/3/2020)
  • 2. HC Wainwright analysts commented, "We base our $23 price target on probability adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2019 net cash of $2.54/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (5/7/2019)

Has ChemoCentryx been receiving favorable news coverage?

News stories about CCXI stock have been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ChemoCentryx earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for ChemoCentryx.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 2,030,000 shares, a drop of 29.5% from the December 15th total of 2,880,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 5.0% of the company's stock are sold short. View ChemoCentryx's Current Options Chain.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
  • Dr. Rajinder Singh, Sr. VP of Research (Age 52)
  • Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58)

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $43.66.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $2.53 billion and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is http://www.chemocentryx.com/.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]


MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel